Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Exclusive Story 3 Stocks Under $5 With Strong Analyst Upside PotentialAuthored by Chris Markoch. Publication Date: 2/24/2026. 
Key Points - Grab Holdings is gaining analyst support as revenue growth and its first full year of profitability highlight long-term opportunity in Southeast Asia’s expanding digital economy.
- Vaxart offers speculative biotech upside with its oral vaccine platform targeting influenza, norovirus, and COVID-19, creating a high-risk, high-reward setup.
- ThredUp is positioned to benefit from the fast-growing resale market, with strong institutional ownership and industry forecasts pointing to sustained secondhand demand.
- Special Report: [Sponsorship-Ad-6-Format3]
While many investors are rotating out of speculative penny stocks, others still embrace the risk-reward dynamic. Stocks trading under $5 carry significant risk: many are unprofitable, and some generate little or no revenue. In almost every case these are small-cap companies, which have been beaten up in recent years. Even as the Russell 2000 shows signs of recovery, gains haven't broadly filtered through the small-cap sector. That could change in 2026 if the economic outlook improves—money may flow back into speculative names. But as with any market segment, quality matters. One way to filter for quality is positive analyst sentiment. The three stocks below fit that bill — each lets investors start a sizable position with a modest outlay and still offers meaningful upside potential over the next five years. Profitability Milestone Meets Long-Term Emerging Market Growth Emerging market stocks are expected to be among the winners in 2026, but that hasn't been the case so far for Grab Holdings Inc. (NASDAQ: GRAB), which is down about 15% year-to-date. Based in Singapore, Grab operates a super app that combines technology, e-commerce and fintech. A key reason for the pullback is its proposed merger with Indonesian ride-share competitor Go To. The deal isn't final and could face legislative changes in Indonesia that might limit the company's earnings potential there. The company also missed the top line slightly in its Q4 2025 earnings report. Still, revenue rose 19% year over year, and the period marked the company's first full year of profit. Analysts are forecasting roughly 120% earnings growth over the next 12 months. That helps explain why sentiment remains bullish. GRAB stock has a consensus price target of $6.47, about 54% above the current price. High-Risk Biotech With Platform Potential Biotech is a frequent hunting ground for penny-stock investors, balancing high risk with high reward. One name to watch is Vaxart Inc. (OTCMKTS: VXRT), the only company on this list that meets the classic penny-stock definition — trading just over $0.60 per share at the time of writing. Analyst coverage is light: the only analyst to rate VXRT in the past 12 months has a Buy rating and a $2 target. It's not unusual for analysts to overlook some biotech firms. Vaxart is a clinical-stage company, meaning all of its candidates remain in clinical trials. The upside, however, is clear — the company is testing oral vaccines for influenza, norovirus and COVID-19. Beyond convenience and avoiding needle aversion, Vaxart says its oral platform may induce a broader immune response that could provide wider protection. Institutional ownership is about 18%, yet dollar-volume inflows outnumber outflows nearly 10-to-1, which is noteworthy for such a small-cap, low-priced stock. Resale Tailwinds Could Turn Today's Losses Into Tomorrow's Gains ThredUp Inc. (NASDAQ: TDUP) is down roughly 33% in 2026, but over the past 12 months it's up more than 66%. That suggests this may be a routine pullback amid a market rotation away from unprofitable companies. In ThredUp's case, add the caveat "yet." The company operates an online consignment and thrift marketplace that is gaining traction with Gen Z — revenue rose 12.5% year over year in the most recent quarter. ThredUp cites a GlobalData 2025 market survey forecasting the U.S. secondhand market's gross merchandise value will grow at a compound annual growth rate (CAGR) of 9% through 2029. Institutions own about 89% of TDUP. Dollar buying has outpaced selling two-to-one, and buyer count has outnumbered seller count three-to-one. Still, short interest is roughly 17%, which can add near-term volatility. The six-analyst consensus price target is $12.50, more than 190% above the current price.
| 
